Frontiers in allergy最新文献_第7页

Frontiers in allergy Pub Date : 2024-05-28 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1387525

Cristine Secco Rosario, Marilyn Urrutia-Pereira, Margarita Murrieta-Aguttes, Gennaro D'Amato, Debora Carla Chong-Silva, Ricardo Henrique Moreton Godoi, Nelson A Rosario Filho

引用次数: 0

Omalizumab for the reduction of allergic reactions to foods: a narrative review. 用于减轻食物过敏反应的奥马珠单抗：综述。

Frontiers in allergy Pub Date : 2024-05-28 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1409342

Hafsa Ghouri, Ashna Habib, Zainab Nazir, Nimerta Lohana, Aymar Akilimali

{"title":"Omalizumab for the reduction of allergic reactions to foods: a narrative review.","authors":"Hafsa Ghouri, Ashna Habib, Zainab Nazir, Nimerta Lohana, Aymar Akilimali","doi":"10.3389/falgy.2024.1409342","DOIUrl":"10.3389/falgy.2024.1409342","url":null,"abstract":"<p><p>The frequency of food allergies varies between 2% and 10%, depending on characteristics including age, region, race, and method of diagnosis self-reported by patients or oral food challenges (OFCs). The most common allergies reported are tree nuts (1.2%), milk (1.9%), peanuts (2.2%), and shellfish (1.3%). Omalizumab injection has now been approved by the FDA for the treatment of immunoglobulin E-mediated food allergies in specific adults and children aged one year or older. This medication reduces the risk of allergic reactions (Type I), which can include anaphylaxis, when an individual accidentally encounters one or more food allergens. Omalizumab functions by binding to IgE and altering IgE-mediated pathways, which lessens IgE's capacity to cause allergic reactions. Promising outcomes from clinical trials and case studies include lowered anaphylactic risk and enhanced tolerance to allergens. Omalizumab, however, may have adverse effects; thus, close observation is required. Overall, this review sheds light on the efficacy, safety, and clinical implications of omalizumab, highlighting its potential as a useful intervention for IgE-mediated food allergies.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11172673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapeutic implications on targeting the cytokines produced in rhinovirus-induced immunoreactions. 针对鼻病毒诱导的免疫反应中产生的细胞因子的免疫治疗意义。

Frontiers in allergy Pub Date : 2024-05-27 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1427762

Le Sang, Xia Gong, Yunlei Huang, Linling Zhang, Jian Sun

引用次数: 0

Editorial: 2022 in review: allergen immunotherapy 社论：2022 年回顾：过敏原免疫疗法

Frontiers in allergy Pub Date : 2024-05-23 DOI: 10.3389/falgy.2024.1431413

Linda Cox, Mike Kulis

引用次数: 0

5-HTP inhibits eosinophilia via intracellular endothelial 5-HTRs; SNPs in 5-HTRs associate with asthmatic lung function 5-HTP 通过细胞内皮 5-HTR 抑制嗜酸性粒细胞增多；5-HTR 的 SNP 与哮喘患者的肺功能有关

Frontiers in allergy Pub Date : 2024-05-23 DOI: 10.3389/falgy.2024.1385168

Matthew T. Walker, Jeffrey C. Bloodworth, Timothy S. Kountz, Samantha L. McCarty, Jeremy E. Green, R. Ferrie, Jackson A. Campbell, Samantha H. Averill, Kenneth B. Beckman, L. Grammer, C. Eng, Pedro C. Avila, H. Farber, W. Rodriguez-Cintron, J. Rodriguez-Santana, D. Serebrisky, S. Thyne, M. Seibold, E. Burchard, Rajesh Kumar, J. Cook-Mills

{"title":"5-HTP inhibits eosinophilia via intracellular endothelial 5-HTRs; SNPs in 5-HTRs associate with asthmatic lung function","authors":"Matthew T. Walker, Jeffrey C. Bloodworth, Timothy S. Kountz, Samantha L. McCarty, Jeremy E. Green, R. Ferrie, Jackson A. Campbell, Samantha H. Averill, Kenneth B. Beckman, L. Grammer, C. Eng, Pedro C. Avila, H. Farber, W. Rodriguez-Cintron, J. Rodriguez-Santana, D. Serebrisky, S. Thyne, M. Seibold, E. Burchard, Rajesh Kumar, J. Cook-Mills","doi":"10.3389/falgy.2024.1385168","DOIUrl":"https://doi.org/10.3389/falgy.2024.1385168","url":null,"abstract":"Previous research showed that 5-hydroxytryptophan (5HTP), a metabolic precursor of serotonin, reduces allergic lung inflammation by inhibiting eosinophil migration across endothelial monolayers.It is unknown if serotonin receptors are involved in mediating this 5HTP function or if serotonin receptor (HTR) single nucleotide polymorphisms (SNPs) associate with lung function in humans.Serotonin receptor subtypes were assessed by qPCR, western blot, confocal microscopy, pharmacological inhibitors and siRNA knockdown. HTR SNPs were assessed in two cohorts.Pharmacological inhibition or siRNA knockdown of the serotonin receptors HTR1A or HTR1B in endothelial cells abrogated the inhibitory effects of 5HTP on eosinophil transendothelial migration. In contrast, eosinophil transendothelial migration was not inhibited by siRNA knockdown of HTR1A or HTR1B in eosinophils. Surprisingly, these HTRs were intracellular in endothelial cells and an extracellular supplementation with serotonin did not inhibit eosinophil transendothelial migration. This is consistent with the inability of serotonin to cross membranes, the lack of selective serotonin reuptake receptors on endothelial cells, and the studies showing minimal impact of selective serotonin reuptake inhibitors on asthma. To extend our HTR studies to humans with asthma, we examined the CHIRAH and GALA cohorts for HTR SNPs that affect HTR function or are associated with behavior disorders. A polygenic index of SNPs in HTRs was associated with lower lung function in asthmatics.Serotonin receptors mediate 5HTP inhibition of transendothelial migration and HTR SNPs associate with lower lung function. These results may serve to aid in design of novel interventions for allergic inflammation.","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141106736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Managing cow's milk protein allergy during the 2022 formula shortage: decision-making among pediatric healthcare providers 2022 年配方奶粉短缺期间的牛奶蛋白过敏管理：儿科医疗服务提供者的决策

Frontiers in allergy Pub Date : 2024-05-22 DOI: 10.3389/falgy.2024.1359103

Lea Oliveros, Jerry M. Brown, A. Fabbrini, A. Farrar, Luke Lamos, J. Florio, Jesse Beacker, Jessica V Baran, Michael J Wilsey

{"title":"Managing cow's milk protein allergy during the 2022 formula shortage: decision-making among pediatric healthcare providers","authors":"Lea Oliveros, Jerry M. Brown, A. Fabbrini, A. Farrar, Luke Lamos, J. Florio, Jesse Beacker, Jessica V Baran, Michael J Wilsey","doi":"10.3389/falgy.2024.1359103","DOIUrl":"https://doi.org/10.3389/falgy.2024.1359103","url":null,"abstract":"Cow's milk protein allergy (CMPA) affects 2%-7% of infants and is managed with hypoallergenic formulas. The 2022 recalls of infant formulas due to factors including contamination led to specialty formula shortages, highlighting CMPA management challenges. Understanding healthcare providers' (HCPs) decision-making in transitioning to alternative formulas during shortages is crucial. Limited attention has been given to how pediatric physicians make these choices.This study utilized US HCPs' de-identified survey data to assess driving factors when switching extensively hydrolyzed formulas during shortages.104 eligible HCPs participated, including general pediatrics, pediatric allergy/immunology, and pediatric gastroenterology specialists. Safety, tolerability, and efficacy were identified as top factors for switching formulas. Formula 1 was considered well-tolerated, patient-accepted, and safe by all HCPs. Most expressed strong belief in Formula 1's safety and effectiveness.Findings inform CMPA management during shortages, offering guidance to HCPs for suitable formula selection and enhanced infant care.","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141108504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial: 2022 in review: food allergy 社论：2022 年回顾：食物过敏

Frontiers in allergy Pub Date : 2024-05-20 DOI: 10.3389/falgy.2024.1429903

Angel Mazon, A. Muraro, Alexandra F. Santos, Ronald van Ree

引用次数: 0

Pre-asthma: a useful concept? A EUFOREA paper. Part 2—late onset eosinophilic asthma 前哮喘：一个有用的概念？EUFOREA 的论文。第二部分--晚发嗜酸性粒细胞性哮喘

Frontiers in allergy Pub Date : 2024-05-15 DOI: 10.3389/falgy.2024.1404735

G. Scadding, C. Gray, D. M. Conti, M. McDonald, V. Backer, G. Scadding, M. Bernal-Sprekelsen, E. De Corso, Z. Diamant, C. Hopkins, M. Jesenak, P. Johansen, J. Kappen, J. Mullol, D. Price, S. Quirce, S. Reitsma, S. Toppila-Salmi, B. Senior, J. P. Thyssen, U. Wahn, P. Hellings

引用次数: 0

Novel insights into the ontogeny of basophils 嗜碱性粒细胞发育的新发现

Frontiers in allergy Pub Date : 2024-05-13 DOI: 10.3389/falgy.2024.1402841

Kensuke Miyake, Junya Ito, Hajime Karasuyama

引用次数: 0

A canine model to evaluate the effect of exercise intensity and duration on olfactory detection limits: the running nose 评估运动强度和持续时间对嗅觉检测极限影响的犬类模型：跑步鼻子

Frontiers in allergy Pub Date : 2024-05-09 DOI: 10.3389/falgy.2024.1367669

Edgar O. Aviles-Rosa, Jöerg Schultz, Michele N. Maughan, Jenna D. Gadberry, Dana M. DiPasquale, Brian Farr, Andrea Henderson, Eric M. Best, Dakota R. Discepolo, Patricia E. Buckley, Erin B. Perry, Debra L. Zoran, Nathaniel J. Hall

{"title":"A canine model to evaluate the effect of exercise intensity and duration on olfactory detection limits: the running nose","authors":"Edgar O. Aviles-Rosa, Jöerg Schultz, Michele N. Maughan, Jenna D. Gadberry, Dana M. DiPasquale, Brian Farr, Andrea Henderson, Eric M. Best, Dakota R. Discepolo, Patricia E. Buckley, Erin B. Perry, Debra L. Zoran, Nathaniel J. Hall","doi":"10.3389/falgy.2024.1367669","DOIUrl":"https://doi.org/10.3389/falgy.2024.1367669","url":null,"abstract":"Detection canines serve critical roles to support the military, homeland security and border protection. Some explosive detection tasks are physically demanding for dogs, and prior research suggests this can lead to a reduction in olfactory detection sensitivity. To further evaluate the effect of exercise intensity on olfactory sensitivity, we developed a novel olfactory paradigm that allowed us to measure olfactory detection thresholds while dogs exercised on a treadmill at two different exercise intensities. Dogs (n = 3) showed a decrement in olfactory detection for 1-bromooctane at 10−3 (v/v) dilutions and lower under greater exercise intensity. Dogs' hit rate for the lowest concentration dropped from 0.87 ± 0.04 when walking at low intensity to below 0.45 ± 0.06 when trotting at moderate intensity. This decline had an interaction with the duration of the session in moderate intensity exercise, whereby dogs performed near 100% detection in the first 10 min of the 8 km/h session, but showed 0% detection after 20 min. Hit rates for high odor concentrations (10−2) were relatively stable at both low (1 ± 0.00) and moderate (0.91 ± 0.04) exercise intensities. The paradigm and apparatus developed here may be useful to help further understand causes of operationally relevant olfactory detection threshold decline in dogs.","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140994354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0